Recent News

• 11.25.2025 - LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
• 10.29.2025 - LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
• 10.16.2025 - LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
• 09.10.2025 - LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
• 09.03.2025 - LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
• 08.25.2025 - 24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Recent Filings

• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 10.27.2025 - DEF 14A Other definitive proxy statements
• 10.16.2025 - PRE 14A Other preliminary proxy statements
• 09.11.2025 - 8-K Current report
• 09.11.2025 - EX-99.1 EX-99.1
• 09.10.2025 - 3 Initial statement of beneficial ownership of securities
• 09.04.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 8-K Current report